Neurogene (NGNE) EBITDA (2013 - 2026)

Neurogene (NGNE) has 14 years of EBITDA data on file, last reported at -$33.3 million in Q1 2026.

• Quarterly EBITDA fell 28.67% year-over-year to -$33.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$110.8 million (down 23.41% YoY) and the FY2025 annual result came in at -$103.3 million, down 25.09% from the prior year.
• EBITDA fell to -$33.3 million in Q1 2026, from -$27.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$11.7 million in Q4 2022 to a low of -$33.3 million in Q1 2026.
• A 5-year average of -$19.5 million and a median of -$18.8 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA climbed 23.09% — and 2024, when it tumbled 59.84%.
• Tracing NGNE's EBITDA over 5 years: stood at -$11.7 million in 2022, then dropped by 26.24% to -$14.7 million in 2023, then sank by 46.01% to -$21.5 million in 2024, then declined by 27.97% to -$27.5 million in 2025, then dropped by 21.14% to -$33.3 million in 2026.
• The last three EBITDA figures came in at -$33.3 million (Q1 2026), -$27.5 million (Q4 2025), and -$23.8 million (Q3 2025), per Business Quant data.